抗血小板口服
Acute coronary syndrome or MI: To reduce the risk of cardiovascular death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. Ticagrelor also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS.
Minor ischemic stroke (NIHSS score ≤5) or high-risk transient ischemic attack (ABCD2 score ≥4): To reduce the risk of stroke <20210923>

P2Y12 Antagonist; Antiplatelet Agent
Ticagrelor and its equipotent metabolite (AR-C124910XX) reversibly interact with the platelet P2Y(12) ADP-receptor, thereby preventing signal transduction and platelet activation and aggregation.

Absorption:
Bioavailability: 36 %
Distribution:
plasma protein binding : >99 %
Metabolism:
Hepatic via CYP3A4/5 to active metabolite
Pharmacodynamics:
1. Onset of inhibition of platelet aggregation (IPA): (180 mg loading dose) ~41% within 30 minutes
2. Elimination Half-life: Parent drug: ~7 hrs; Active metabolite: ~9 hrs; Ticagrelor and its metabolite AR-C124910XX are eliminated in feces with less than 1% found in urine

1. Hypersensitivity to ticagrelor
2. History of ICH (intracranial hemorrhage);
3. Active bleeding (eg, peptic ulcer or intracranial hemorrhage)
4. Severe liver impairment

C

Excretion into breast milk is unknown; use is not recommended.

Dyspnea (13.8%); Major and minor bleeding (8.7%); serum creatinine increased (7%; mechanism undetermined).

Acute Coronary Syndrome (ACS):
Loading dose: Ticagrelor 180 mg orally once plus aspirin (usually 325 mg).
Maintenance dose: Ticagrelor 90 mg twice daily with aspirin 75 to 100 mg once daily.
For patients with ACS who have undergone percutaneous coronary intervention (PCI) and have an increased risk of bleeding, discontinuation of aspirin may be considered after 3 months, BRILINTA as single antiplatelet therapy should be continued for 9 months.<20241226>

Myocardial Infarction (MI): Ticagrelor 60 mg orally twice daily.

Minor Ischemic Stroke or High-Risk Transient Ischemic Attack:
Initial dose: Ticagrelor 180 mg orally once in combination with aspirin (loading dose 300-325 mg once).
Maintenance dose: Ticagrelor 90 mg twice daily in combination with aspirin (maintenance dose 75-100 mg once daily) for 30 days.

May be taken without regard to meals.

急性冠狀動脈症候群 (ACS)：
初始劑量：Ticagrelor 180 mg 口服一次，併用Aspirin (通常為325 mg)。
維持劑量：Ticagrelor 90 mg 每日兩次，併用Aspirin 75 至 100 mg 每日一次。
對於曾接受經皮冠狀動脈介入治療 (PCI) 且出血風險增加的ACS患者，可考慮在3個月後停用Aspirin，Brilinta作為單一抗血小板療法應持續9個月。<20241226>

心肌梗塞 (MI)：Ticagrelor 60 mg 口服每日兩次。

小型缺血性中風或高風險短暫性腦缺血發作：
初始劑量：Ticagrelor 180 mg 口服一次，併用Aspirin (初始劑量300-325 mg一次)。
維持劑量：Ticagrelor 90 mg 每日兩次，併用Aspirin (維持劑量75-100 mg 每日一次)，持續30天。

可不受餐食影響服用。